Suppr超能文献

多粘菌素和利福平对印度南部一家三级护理医院耐碳青霉烯菌的体外活性

Invitro Activities of Polymyxins and Rifampicin against Carbapenem Resistant at a Tertiary Care Hospital from South India.

作者信息

Muthusamy Dheepa, Sudhishnaa S, Boppe Appalaraju

机构信息

Associate Professor, Department of Microbiology, Government Medical College & ESIC Hospital , Coimbatore, Tamil Nadu, India .

Student, PSG Institute of Medical Sciences & Research , Peelamedu, Coimbatore, Tamil Nadu, India .

出版信息

J Clin Diagn Res. 2016 Sep;10(9):DC15-DC18. doi: 10.7860/JCDR/2016/19968.8535. Epub 2016 Sep 1.

Abstract

INTRODUCTION

() is rapidly emerging as a potent organism causing a multitude of nosocomial infections. The organism also carries various resistance mechanisms to antibiotics, making treatment more difficult. Very few choices are left, as strains have begun to develop resistance against cephalosporins, aminoglycosides and even carbapenems.

AIM

To examine the sensitivity pattern of three older antibiotics namely colistin, polymyxin B and rifampicin against carbapenem resistant by disk diffusion method and the sensitivity of colistin alone by Minimum Inhibitory Concentration (MIC) determination by VITEK automated system.

MATERIALS AND METHODS

Hundred clinical isolates of carbapenem resistant were tested for sensitivity to colistin, polymyxin B and rifampicin by Kirby-Bauer disk diffusion method. They were also tested for sensitivity to colistin by VITEK 2C (biomérieux) automated microbial identification system. The zone diameters and Minimum Inhibitory Concentration values for the above two methods, respectively were observed and analysed. All the Antibiotic Susceptibility Tests were done according to the CLSI guidelines.

RESULTS

By Kirby-Bauer disk diffusion method, 78% of the carbapenem resistant strains were found to be sensitive, 12% intermediate sensitive and 10% resistant to colistin. All the isolates were sensitive to polymyxin B and 80% were resistant to rifampicin. By the VITEK automated system, 99% of the isolates were sensitive to colistin (more in number than by disk diffusion method).

CONCLUSION

Polymyxins (colistin - polymyxin E and polymyxin B) are the next choice for multidrug resistant serious nosocomial infections like those of , till newer antibiotics are discovered to treat such infections. Rifampicin resistance was found to be very high and hence, is not advised for monotherapy.

摘要

引言

(某病原体名称)正迅速成为引发多种医院感染的强效病原体。该病原体还具有多种抗生素耐药机制,使得治疗更加困难。由于(某病原体名称)菌株已开始对头孢菌素、氨基糖苷类抗生素甚至碳青霉烯类抗生素产生耐药性,可供选择的治疗药物已寥寥无几。

目的

通过纸片扩散法检测三种较老的抗生素即黏菌素、多黏菌素B和利福平对耐碳青霉烯类(某病原体名称)的敏感性模式,并通过VITEK自动化系统采用最低抑菌浓度(MIC)测定法单独检测黏菌素的敏感性。

材料与方法

采用 Kirby - Bauer纸片扩散法对100株耐碳青霉烯类(某病原体名称)临床分离株进行黏菌素、多黏菌素B和利福平的敏感性检测。还通过VITEK 2C(生物梅里埃公司)自动化微生物鉴定系统对它们进行黏菌素敏感性检测。分别观察并分析上述两种方法的抑菌圈直径和最低抑菌浓度值。所有抗生素敏感性试验均按照CLSI指南进行。

结果

通过Kirby - Bauer纸片扩散法,发现78%的耐碳青霉烯类菌株对黏菌素敏感,12%为中度敏感,10%耐药。所有分离株对多黏菌素B敏感,80%对利福平耐药。通过VITEK自动化系统,99%的分离株对黏菌素敏感(数量比纸片扩散法更多)。

结论

在发现新的抗生素用于治疗此类感染之前,多黏菌素(黏菌素 - 多黏菌素E和多黏菌素B)是治疗多重耐药严重医院感染(如由某病原体名称引起的感染)的次选药物。发现利福平耐药性非常高,因此不建议单药治疗。

相似文献

1
Invitro Activities of Polymyxins and Rifampicin against Carbapenem Resistant at a Tertiary Care Hospital from South India.
J Clin Diagn Res. 2016 Sep;10(9):DC15-DC18. doi: 10.7860/JCDR/2016/19968.8535. Epub 2016 Sep 1.
6
Susceptibility profile of and metallo-β-lactamases co-harbouring isolates of carbapenem resistant (CRAB) against standard drugs and combinations.
Front Cell Infect Microbiol. 2023 Jan 6;12:1068840. doi: 10.3389/fcimb.2022.1068840. eCollection 2022.
10
Antibiotic Resistance Pattern Of Acinetobacter Baumannii Isolated From Bacteremia Patients In Pakistan.
J Ayub Med Coll Abbottabad. 2022 Jan-Mar;34(1):95-100. doi: 10.55519/JAMC-01-9105.

引用本文的文献

1
in the critically ill: complex infections get complicated.
Front Microbiol. 2023 Jun 22;14:1196774. doi: 10.3389/fmicb.2023.1196774. eCollection 2023.
2
Virulence Characteristics of Biofilm-Forming in Clinical Isolates Using a Model.
Microorganisms. 2021 Nov 16;9(11):2365. doi: 10.3390/microorganisms9112365.
3
Biology of : Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options.
Front Cell Infect Microbiol. 2017 Mar 13;7:55. doi: 10.3389/fcimb.2017.00055. eCollection 2017.

本文引用的文献

1
In Vitro Activity of Tigecycline and Colistin against clinical isolates of Acinetobacter baumannii in Hospitals in Tehran and Bandar-Abbas, Iran.
Electron Physician. 2014 Jul 1;6(3):919-24. doi: 10.14661/2014.919-924. eCollection 2014 Jul-Sep.
3
Colistin: an update on the antibiotic of the 21st century.
Expert Rev Anti Infect Ther. 2012 Aug;10(8):917-34. doi: 10.1586/eri.12.78.
4
Acinetobacter baumannii: an emerging opportunistic pathogen.
Virulence. 2012 May 1;3(3):243-50. doi: 10.4161/viru.19700.
5
Colistin: new lessons on an old antibiotic.
Clin Microbiol Infect. 2012 Jan;18(1):18-29. doi: 10.1111/j.1469-0691.2011.03734.x.
6
Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients.
Ann Intensive Care. 2011 Aug 2;1(1):30. doi: 10.1186/2110-5820-1-30.
7
Polymyxins: Antimicrobial susceptibility concerns and therapeutic options.
Indian J Med Microbiol. 2011 Jul-Sep;29(3):230-42. doi: 10.4103/0255-0857.83905.
10
Treatment of Acinetobacter infections.
Clin Infect Dis. 2010 Jul 1;51(1):79-84. doi: 10.1086/653120.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验